|
WO2016028985A2
|
|
Method for treating hyperhidrosis
|
|
US2015119378A1
|
|
Azetidinyloxy-, pyrrolidinyloxy-, and piperidinyloxy-substituted metanicotines as neuronal nicotinic acetylcholine receptor ligands
|
|
US2014066460A1
|
|
Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
|
|
WO2014011863A1
|
|
Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
|
|
WO2014004417A1
|
|
Nicotinic receptor non-competitive antagonists
|
|
WO2013184732A1
|
|
Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate
|
|
US2013308840A1
|
|
Chemical entity search, for a collaboration and content management system
|
|
US2013253067A1
|
|
Method of treating bladder disorders
|
|
US2015031675A1
|
|
Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof
|
|
EP2773609A2
|
|
Nicotinic receptor non-competitive modulators
|
|
AU2012238322A1
|
|
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
TW201311698A
|
|
1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands
|
|
AU2012205208A1
|
|
Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
|
|
WO2012129262A1
|
|
Treatment of attention deficit/hyperactivity disease
|
|
WO2012125518A1
|
|
Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
|
|
BR112013018296A2
|
|
treatment of cognitive dysfunctions in schizophrenia
|
|
CA2823848A1
|
|
Nicotinic receptor non-competitive antagonists
|
|
CN102918021A
|
|
Nicotinic receptor non-competitive antagonists
|
|
UA108500C2
|
|
Noncompetitive antagonists of nicotinic receptors
|
|
WO2011112428A2
|
|
Arylvinylazacycloalkane compounds for constipation
|
